Yes, they are the result of the reverse split and are difficult to trade. I talked to TD Ameritrade about them and even though they are difficult to trade, you can exercise them if you want to. For example, if you bought the non-standard $2 put (before the reverse split), you can exercise it and put your stock to the put seller for $20/share.
Less successful is Samsung’s take on the fingerprint-unlock system made popular by Apple with the iPhone 5S. Like the 5S, the S5’s home key features an integrated fingerprint scanner, which can be used to unlock the phone or authenticate purchases online (Samsung is partnering with PayPal to enable this feature, though it doesn’t validate purchases from the Google Play Store). Samsung’s version requires a vertical swipe over the home button to activate the scanner, and we found it to be quite unreliable and virtually impossible to activate when holding the phone in one hand. It can store up to three different digits, but it was very particular about the speed and orientation of the swiping motion used — if we weren’t doing a perfectly straight swipe down, it would refuse to unlock the phone.
Sentiment: Strong Sell
"Growth in worldwide smartphone shipments is expected to slow significantly in 2014, as the devices start to saturate several mature markets, according to researcher International Data Corp.
IDC's Ryan Reith said 2014 will be "an enormous transition year for the smartphone market," with growth declining " more than ever before."
Another high level manager signaling a top in SYNA stock.
Looks like a January to March, 2014 quarterly miss in revenue and EPS.
Look out for a revenue and profit warning soon.
He has 8617 shares left.
Probably sees a top and a January to March quarterly earnings miss.
BEIJING, Feb 13 (Reuters) - The explosive growth of smartphone sales in China, the world's biggest smartphone market, has come to a halt as unit shipments declined for the first time in more than two years, data firm IDC said on Thursday.
Shipments of smartphones in China fell 4.3 percent to 90.8 million in the fourth quarter from 94.8 million units in the previous one, the first drop-off since the second quarter of 2011, according to IDC.
"The world has increasingly looked to China as the powerhouse to propel the world's smartphone growth and this is the first hiccup we've seen in an otherwise stellar growth path," said Melissa Chau, a senior research manager with IDC.
"We are now starting to see a market that is becoming less about capturing the low-hanging fruit of first time smartphone users and moving into the more laborious process of convincing existing users why they should upgrade to this year's model."
The following is the CURRENT timeline for achieving (or not) the First Sales Milestone of $2/share. (FSM)
It will change as other countries make their "First Commercial Sale"
Q1: German sales count towards FSM
Q2: German sales count towards FSM. Also April 1, 2014 is considered the "Product Launch" date
Q3: German sales count towards FSM
Q4: German sales count towards FSM
Q2: non-Major Markets sales count toward FSM
Q3: non-Major Markets sales count toward FSM
Q4: non-Major Markets sales count toward FSM
Note: Major Markets (US, UK, Spain, France, Germany, Italy) "First Commercial Sale" must occur before the end of 2015.
Q1: non-Major Markets sales count toward FSM
2017 and beyond
No sales in any market count toward FSM#1
Read my recent post:
"What we'd like to see from Germany in April 2014 ($15 million in sales for Q1)"
The appeal process will take a long time I suspect because the FDA is inept and incompetent. Sanofi is preparing an appeal and close to filing the appeal.
There are lots of Seeking Alpha articles you can read to get info.
Google "GCVRZ" and "Chris DeMuth"
Any investment in GCVRZ will take a long time to play out. Probably 2-3 years.
If you own 200K of GPT, you already ARE a millionaire.
200,000 shares times $5.76 = $1,152,000
Cogratulations! Unless you are on margin.
In April, Sanofi will report the first quarter of Lemtrada revenue from Germany. These are the first sales that will count toward the First Sales Milestone of $400 million.
What would be a good number?
There are currently three groups of revenue that can contribute to the First Sales Milestone:
1. Major Markets (excluding the US). Germany, France, Spain, Italy, and the UK
2. non-Major Markets we know of that have approved Lemtrada: Canada, Australia, Mexico.
3. non-Major Markets that we do not know that have approved Lemtrada: 29 countries that probably include some European countries like Belgium, The Netherlands, Switzerland, Luxembourg, Poland, etc.
1. Major Markets:
Germany's population is 82 million
France's population is 66 million
Italy's population is 61 million
Spain's population is 47 million
The UK's population is 63 million
Total Major Market population = 319 million
2. Non-Major Markets that we know of:
Canada's population is 35 million
Australia's population is 23 million
(I am leaving out Mexico because it may be too poor to contribute much revenue)
Total non-Major population = 58 million
3. Some Non-Major Markets that we do not know of:
Belgium's population is 11 million
The Netherlands' population is 16 million
Switzerland's population is 8 million
Austria's population is 8 million
Sweden's population is 9 million
Total non-Majors we don't know of population = 52 million
Total = 429 million
Assume the MS population is evenly distributed..
We need $400 total to reach the First Sales Milestone.
Germany is 82/429ths of the total population = 19.1%
In 4 quarters, Germany needs to bring in $19.1% of $400 million = $76.5 million.
In 1 quarter, Germany needs to bring in 1/4 of $76.5 million = $19.1 million.
We need to see Germany report at least $15 million in sales when they report Q1 sales in April, 2014.
$15 million is good because:
a) there are more countries contributing to the First Sales Milestone.
b) The trend in sales is usually up.
Sentiment: Strong Buy
Oops, I made a mistake.
The sales data for April, 2014 WILL be significant for Germany because Germany's 4 quarter sales data to be included in the First Sales Milestone runs from January 1, 2014 to December 31, 2014. April 2014's Germany sales data may cause a significant upside or downside move in the GCVRZ price.
One other thing to remember. There are 6 so-called "Major Markets", i.e. the US, France, Italy, Germany, Spain, and the UK. All other markets are "non-Major Markets" and the sales data that is counted toward the First Major Milestone for these 26 countries is not counted until the period from April 1, 2015 to March 31, 2016. So, you can see that the drama might not end until the end of 2015 when most of the "non-Major Market" data from the other 26 countries (and counting?) comes in. Here's an extract from a recent Seeking Alpha article:
"In addition to these six major markets, Lemtrada sales in other nations that occur between April 1, 2015 and March 31, 2016 will also be included in the calculation to determine whether or not this first milestone is achieved. On December 13, 2013, Sanofi announced that Canada approved Lemtrada, and on December 19 the drug received Australian approval. Therefore, it is already evident that a great many nations should contribute revenue towards a potential reaching of this initial milestone, and the corresponding $2 payment holders would then receive."
None of the revenue numbers from any country are included in any country's First Sales Milestone revenue when sales data is reported in April 2014. The trend for Germany might be significant but even Germany's sales data reported in April 2014 is not counted in Germany's First Sales Milestone.
The first time any sales data for any country is included in its First Sales Milestone numbers is when data for Q2 is reported in July 2014. Even then, only the German data is included.
There's no real digital event in the near future except for a possible successful appeal to the FDA. The other potential digital event could be if Germany reports surprisingly high Q2 sales in July 2014,then the CVRs would jump significantly.
The most important data event will probably be in October 2014 when the majority of the 32 countries that have approved Lemtrada start reporting their Q3 sales figures.
Up until that point, it's all going to be speculation and guessing.
My guess is that it's probably going to be in the first two weeks of April since the sales data is quarterly based because of the milestones. Last update was on Jan. 16th, 2014, so around April 16th.
Note this sentence from the quote from the conference call:
"We fully expect that 3 quarters of this world (1.7 million patients) will have access to Lemtrada"
That means: 1.275 million patients will have access to Lemtrada! Excluding the US.
If only 4% of these 1.275 million patients generate Lemtrada revenue in 2014 and 2015, the First Sales Milestone goal is surpassed. I like these odds.
Five Items from the conference call:
1. The number of patients worldwide that are affected with MS is 2.1 million.
2. The number of patients in the US that are affected with MS is 400,000.
3. Outside of the US, there are 1.7 million patients that are affected with MS.
4. Lemtrada is already approved in 32 countries (and counting).
5. Sanofi is in the process of appealing the US decision.
1. The one year highest potential Lemtrada revenue from all worldwide patients is $50,000 times 1.7 million = $85 Billion.
2. Since this is an obviously unrealistic goal, let's say that ONLY 3% of all worldwide patients use Lemtrada in 2014 and 2015 (the time frame of the First Sales Milestone) AND that they only pay an average of ONLY $25,000. This is a total of $1.275 Billion in revenue. This revenue is 3 TIMES the $400 million First Sales Milestone which pays $2. It also brings us closer to the Second Sales Milestone of $1.8 Billion which pays $3.
3. Note that this calculation completely ignores the possibility that any patient would have taken Lemtrada in BOTH 2014 and 2015, as indicated. The revenue from these patients would be significantly higher than from patients that only took it once in either 2014 or 2015.
4. The figures from Item 2 (US patients = 400,000) and Item 3 above (Worldwide patients = 1.7 million) suggests that the US has 19% of worldwide MS patients. Seems high! The US population is only 4% of the world population!
5. Do these numbers suggest that reaching the First Sales Milestone is likely?
A quote from the conference call:
"I think it's important to put this in a bit of context. As we look at the overall franchise and the unmet medical need in the multiple sclerosis market, U.S. patients represent about 400,000 out of the 2.1 million patients affected with MS. And we fully expect that 3 quarters of this world will have access to Lemtrada,and we'll continue to work with the FDA to find hopefully a path forward."
This is huge! 15,000 MS patients in Mexico paying $50,000 for the first year treatment is $750 million
If only 10% of Mexican MS patients use Lemtrada in its first year, Mexico would contribute $75 million to the First Sales Milestone of $400 million.
Population of Mexico is 120 million
Population of Canada is 35 million
Sentiment: Strong Buy
According to Zacks:
Earnings announcement for NES: Mar 10, 2014
Nuverra Environmental Solutions, Inc. is estimated to report earnings on 03/10/2014. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.47. The reported EPS for the same quarter last year was $-0.10.
Looks like the premarket bid is $58